FDA Inspection 1115530 — University of Texas MD Anderson Cancer Center
The FDA completed an inspection of University of Texas MD Anderson Cancer Center on December 12, 2019 in Houston, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 12, 2019
- Fiscal Year
- 2020
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Houston, TX (United States)